CORRECTING and REPLACING Medis Technologies Schedules Fourth Quarter and Year-End Financial Results and Conference Call.Energy Editors/Business Editors/Environment Writers CORRECTION...by Medis Technologies NEW YORK--(BUSINESS WIRE)--March 4, 2004 In BW5296 issued March 4, 2004: First graph, third line should read xxx Thursday, March 11, 2004 (sted Wednesday, March 11, 2004). Also, second graph, fifth line should read xxx Monday, March 15, 2004 (sted Monday, March 16, 2004). The corrected release reads: MEDIS TECHNOLOGIES SCHEDULES FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS AND CONFERENCE CALL Medis Technologies Ltd. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : MDTL MDTL Medis Technologies, Ltd (stock symbol) MDTL Montana Defense Trial Lawyers Association ) ("Medis") announced today that it will issue its financial results for the fourth quarter and year-ended December 31, 2003 on Thursday, March 11, 2004. The results will be released before the opening of the stock market. Management will also conduct a conference call that morning at 10:00 a.m. Eastern Time to discuss fourth quarter and year-end results and the current status of its business operations Business operations are those activities involved in the running of a business for the purpose of producing value for the stakeholders. Compare business processes. The outcome of business operations is the harvesting of value from assets . Interested parties may participate in the call by dialing 800-915-4836 (Domestic) or 973-317-5319 (International) approximately 10 minutes before the call is scheduled to begin and ask to be connected to the Medis conference call. A recorded replay of the call will be available until 5:00 p.m. Eastern Time on Monday, March 15, 2004. Listeners may dial 800-428-6051 (Domestic) or 973-709-2089 (International) and use the code 341229 for the replay. Medis Technologies is involved in the development of highly advanced proprietary technology products primarily related to sources of clean energy for the 21st Century. Medis' primary focus is on direct liquid fuel cell technology. Its business strategy is to license or sell its technologies to, or enter into joint ventures with, large international corporations or sell its products to end users through retail outlets and service providers. In addition to its fuel cell technology, Medis' product pipeline, in varying stages of development, includes inherently conductive polymers, the toroidal engine The Toroidal engine design is a form of internal combustion engine that features pistons that rotate within a toroidal space. To date, no toroidal engine designs have entered production, but the designs are typically simple and have few moving parts, and toroidal engines have a and compressor and stirling cycle system. Medis has also developed the CellScan with many potential applications relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc disease diagnostics and chemo che·mo n. Chemotherapy or a chemotherapeutic treatment. sensitivity. This press release may contain forward-looking statements, which are made pursuant to the safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Such forward-looking statements involve risk and uncertainties, including, but not limited to, the successful completion of product development, the success of product tests, commercialization risks, availability of financing and results of financing efforts. Further information regarding these and other risks is described from time to time in the Company's filings with the SEC. This press release is available on Medis' web site at www.medistechnologies.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion